731-P: CGM-Based Measurements for Once-Weekly Insulin Icodec vs. Once-Daily Insulin Glargine U100 in Insulin-Treated Patients with T2D: A Post-hoc Analysis

Insulin icodec* (icodec) is a once-weekly basal insulin in clinical development. In a phase 2 treat-to-target trial (NCT03922750) in patients with T2D switching from daily insulin (N=154), icodec with an initial 100% loading dose (LD; doubling the first dose) showed greater time in range (TIR, 70-180 mg/dL) vs. insulin glargine U100 (IGlar U100) at weeks 15 and 16 (primary endpoint), as measured by double-blinded Dexcom G6® CGM. This post hoc analysis compared TIR, time above range (TAR, >180 mg/dL) and below range (TBR, 70% TIR and Disclosure H. S. Bajaj: Other Relationship; Self; Eli Lilly and Company, Novo Nordisk, Research Support; Self; Amgen Inc., AstraZeneca, Boehringer Ingelheim International GmbH, Gilead Sciences, Inc., Kowa Pharmaceuticals America, Inc., Merck & Co., Inc., Sanofi, Tricida, Inc. R. Beck bang: Employee; Self; Novo Nordisk A/S. A. Gowda: Employee; Self; Novo Nordisk A/S, Stock/Shareholder; Self; Novo Nordisk A/S. M. M. Koefoed: Employee; Self; Novo Nordisk. P. A. Senior: Other Relationship; Self; Novo Nordisk, Vertex Pharmaceuticals Incorporated, Research Support; Self; Novo Nordisk. R. M. Bergenstal: Advisory Panel; Self; Abbott Diabetes, Eli Lilly and Company, Novo Nordisk, Onduo LLC., Roche , Sanofi, United Healthcare , Consultant; Self; Abbott Diabetes, Ascensia , Dexcom, Inc., Eli Lilly and Company, Hygieia, Johnson & Johnson, Medtronic, Novo Nordisk, Onduo LLC., Roche, Sanofi, United Healthcare, Other Relationship; Self; HealthPartners Institute, Research Support; Self; Abbott Diabetes, Dexcom, Inc., Eli Lilly and Company, Helmsley Charitable Trust, Hygieia, Johnson & Johnson, Medtronic, NIDDK, Novo Nordisk, Onduo LLC., Roche, Sanofi, United Healthcare.